



Sheri Mullen
SVP, US Specialty Business Unit

Sheri leads GSK's Specialty Business in the US pharmaceuticals organization. She was appointed to her current position in October 2018 to build the Specialty Business Unit for the US Pharma business. She has commercial responsibility for leading, developing and managing the strategic performance of the business. Currently, the team is accountable for commercializing Benlysta, the first new drug for the autoimmune disease, Systemic Lupus Erythematosus, in more than 50 years and Nucala, the first biologic targeted at eosinophilic asthma. A dedicated professional who has more than 25 years of commercial experience, Sheri joined GSK in 1990 as a sales representative and held various positions of increasing responsibility in sales, marketing and operations including VP of the Immunology and Rare Diseases Business Unit, VP of Sales for the Oncology Business where she helped successfully launch several new medicines and transform the Oncology commercial model.